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he RGS7 (R7) family of RGS proteins bound to the
divergent G
 
 
 
 subunit G
 
 
 
5 is a crucial regulator of
G protein–coupled receptor (GPCR) signaling in
the visual and nervous systems. Here, we identify R7BP, a
novel neuronally expressed protein that binds R7–G
 
 
 
5
complexes and shuttles them between the plasma mem-
brane and nucleus. Regional expression of R7BP, G
 
 
 
5,
and R7 isoforms in brain is highly coincident. R7BP is
palmitoylated near its COOH terminus, which targets the
protein to the plasma membrane. Depalmitoylation of
T
 
R7BP translocates R7BP–R7–G
 
 
 
5 complexes from the
plasma membrane to the nucleus. Compared with non-
palmitoylated R7BP, palmitoylated R7BP greatly augments
the ability of RGS7 to attenuate GPCR-mediated G protein–
regulated inward rectifying potassium channel activation.
Thus, by controlling plasma membrane nuclear–shuttling
of R7BP–R7–G
 
 
 
5 complexes, reversible palmitoylation of
R7BP provides a novel mechanism that regulates GPCR
signaling and potentially transduces signals directly from
the plasma membrane to the nucleus.
 
Introduction
 
Hundreds of neurotransmitters regulate neuronal development
and function by signaling through G protein–coupled receptors
(GPCRs; for review see Gainetdinov et al., 2004). GPCRs exert
their effects by regulating ion channels, second messenger
production, and protein kinase cascades, which in turn control
neuronal activity, gene expression, plasticity, differentiation,
morphogenesis, and migration.
GPCR signaling is tightly regulated to determine the
sensitivity, kinetics, and fidelity of neuronal activity. Disruption
of GPCR regulatory mechanisms, such as the GPCR phos-
phorylation–arrestin pathway, dramatically affects processes
such as nociception and addiction (for reviews see Chao and
Nestler, 2004; Gainetdinov et al., 2004). GPCR signaling also
is potently regulated by RGS proteins (regulators of G protein
signaling; for review see Hollinger and Hepler, 2002). RGS
proteins attenuate signaling by functioning as GTPase-activating
proteins (GAPs) for G
 
 
 
 subunits (Berman et al., 1996; Hunt et
al., 1996; Watson et al., 1996). Certain RGS proteins, such as
the RGS protein p115RhoGEF (Hart et al., 1998), also function
as G
 
 
 
 effectors.
Among more than 20 RGS family members in vertebrates,
the R7 subfamily consisting of RGS6, RGS7, RGS9-1, RGS9-2,
and RGS11 is emerging as an important set of neuronal
GPCR-signaling regulators. The R7 family is highly expressed
in the central and peripheral nervous systems (Gold et al.,
1997; Zhang et al., 2000; Witherow et al., 2003; Larminie et
al., 2004). R7 proteins selectively deactivate the Gi/o-class of
G
 
 
 
 subunits that mediate the action of GPCRs for many
modulatory neurotransmitters (Posner et al., 1999; Rose et al.,
2000; Hooks et al., 2003). RGS9 is the best understood R7
family member (Cowan et al., 2001; Witherow and Slepak,
2003; Jones et al., 2004). RGS9 potently regulates GPCR-
mediated Ca
 
2
 
 
 
 channel inhibition in striatal neurons (Cabrera-
Vera et al., 2004). RGS9 knockout mice exhibit augmentation
of the antinociceptive and rewarding effects of 
 
 
 
-opioid re-
ceptors and enhancement of the locomotor and rewarding
effects mediated by D2 dopamine receptors (Rahman et al.,
2003; Zachariou et al., 2003). Human or mouse RGS9 mutants
exhibit bradyopsia, a visual defect caused by prolonged acti-
vation of the G
 
 
 
 subunit transducin, resulting in impaired
light adaptation and contrast detection (Chen et al., 2000;
Nishiguchi et al., 2004).
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R7 proteins function as complexes with G
 
 
 
5, a divergent
member of the G
 
 
 
 family (Watson et al., 1994; Jones et al.,
2004). Mice lacking G
 
 
 
5 exhibit visual defects indistinguish-
able from RGS9 knockout mice (Krispel et al., 2003) and high
mortality and slow growth due to destabilization of the entire
R7 family (Chen et al., 2003). In the retina, RGS9-1–G
 
 
 
5L
complexes are anchored to disk membranes by binding the ret-
ina-specific membrane protein R9AP (RGS9-anchoring pro-
tein; Hu and Wensel, 2002). R9AP also stimulates the GAP ac-
tivity of RGS9-1 (Lishko et al., 2002; Hu et al., 2003). R9AP
knockout mice recapitulate the visual phenotypes of RGS9 or
G
 
 
 
5 knockout mice (Keresztes et al., 2004). Likewise, humans
with R9AP or RGS9 mutations exhibit similar defects in visual
perception (Nishiguchi et al., 2004).
Because R9AP is expressed insignificantly in nonretinal
tissues (Hu and Wensel, 2002), the mechanisms that control
subcellular localization and function of R7–G
 
 
 
5 complexes in
the central and peripheral nervous systems are unknown.
However, R7–G
 
 
 
5 localization and function probably are reg-
ulated tightly because these proteins localize both to mem-
branes and nuclei in neurons where they regulate GPCR sig-
naling at the plasma membrane and gene expression in the
nucleus (Zhang and Simonds, 2000; Bouhamdan et al., 2004;
Cabrera-Vera et al., 2004; Krumins et al., 2004; Liu and
Fisher, 2004). Mechanisms that regulate R7–G
 
 
 
5 localization
and function may be neuron-specific because R7 isoforms as-
sociate poorly with the plasma membrane when expressed in
nonneuronal cells (Posner et al., 1999; Chatterjee et al., 2003;
Witherow et al., 2003; Bouhamdan et al., 2004; Liu and
Fisher, 2004; Takida et al., 2005).
Here, we report the identification and characterization of
R7BP, a novel palmitoylated R9AP-related protein that is
highly expressed in the nervous system. We present evidence
indicating that reversible palmitoylation of R7BP controls the
shuttling of R7–G
 
 
 
5 complexes between the plasma mem-
brane and nucleus and the ability of an R7 protein to regulate
GPCR signaling.
 
Results
 
Identification, cloning, and expression of 
R7BP
 
We identified R9AP-like proteins by performing PSI-BLAST
searches of the mouse genome. This identified a novel 257-resi-
due protein that for reasons presented in subsequent paragraphs
was named R7BP (RGS7 family binding protein; Fig. 1, A and
B). Analysis of several genomic and EST databases indicated
that R7BP and R9AP are the only closely related members of
this family (Fig. 1 C; accession numbers listed in Materials and
methods). Both proteins also display weak similarity to SNARE
proteins that mediate vesicular trafficking (unpublished data).
The predicted 
 
R7BP
 
 gene contains six exons and is localized to
chromosome 5q12.3 in humans, 13D1 in mouse, and 2q13 in rat
(unpublished data). R7BP or R9AP homologues were not de-
tected in 
 
Caenorhabditis elegans
 
 or 
 
Drosophila melanogaster
 
,
which do possess G
 
 
 
5 and R7 homologues. Therefore, R7BP
and R9AP evolved after G
 
 
 
5 and the R7 family.
We cloned and sequenced a cDNA encoding the R7BP
ORF from mouse brain, which confirmed database predictions.
A mouse R7BP cDNA sequence assembled from EST data-
bases predicted an mRNA of 
 
 
 
6.4 kb. In the deduced mRNA,
the ORF encoding R7BP apparently is preceded by a GC-rich
(
 
 
 
66%) stretch of 
 
 
 
720 nucleotides containing four short
open reading frames, which could regulate R7BP translation
(for review see Meijer and Thomas, 2002).
R7BP and R9AP exhibit similar domain organizations
(Fig. 1 A). Within their NH
 
2
 
-terminal regions these proteins are
28% identical and 54% similar. Distal to this region is a pre-
dicted coiled-coil domain followed by a putative membrane
localization domain. The membrane localization domain of
R9AP is a transmembrane segment, whereas R7BP contains a
COOH-terminal polybasic sequence and a double cysteine mo-
tif that is an excellent candidate for lipid modification (Zhang
and Casey, 1996; Smotrys and Linder, 2004).
Results of Northern blotting experiments indicated that
R7BP is encoded by an 
 
 
 
6.4-kb mRNA expressed highly in
brain and at much lower levels in other tissues examined (Fig.
2 A), similar to the R7 family and G
 
 
 
5 (Gold et al., 1997;
Zhang et al., 2000; Larminie et al., 2004). There was no indica-
Figure 1. Identification of R7BP. (A) Schematic diagram of R7BP. Mouse
R7BP (RGS7 family binding protein) was identified in PSI-BLAST searches as
the protein most closely related to retinal R9AP (RGS9-anchoring protein).
The deduced R7BP protein is 257 aa in length and consists of a noncon-
served NH2-terminal region of  50 aa, a central domain (residues 48–
151) exhibiting 28% identity and 54% similarity to R9AP, a putative coiled-
coil domain (residues 194–221), and a COOH-terminal domain containing
a polybasic stretch followed by a double-cysteine motif. (B) Protein sequence
alignments of mouse R9AP and R7BP. Identical (black) and similar (gray)
residues are indicated. (C) Multiple sequence alignment of full or partial
R7BP protein sequences deduced from Mus musculus (mouse), Homo sapiens
(human), Gallus gallus (chicken), and Danio rerio (zebrafish) databases.
Identical (black) and similar (gray) residues are indicated. 
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tion of alternative splicing suggested by Northern blotting or
assembly of ESTs (Fig. 2 A and not depicted). Results of in situ
hybridization experiments revealed that R7BP mRNA is highly
expressed in the cerebellum, neocortex, thalamus, hippocam-
pus, striatum, and piriform cortex and is readily detectable in
olfactory bulb, several midbrain nuclei, and hindbrain (Fig. 2,
B and C). This regional expression pattern is largely coincident
with the aggregate expression pattern of the R7 family (Gold et
al., 1997). However, our results do not exclude that some brain
nuclei expressing certain R7 family members at relatively high
levels may poorly express R7BP. R7BP mRNA is also detect-
able in mouse retina, organ of Corti, pituitary, aorta, vein, co-
lon, hematopoetic stem cells, spinal cord, and embryonic heart,
as indicated by EST database searches.
 
R7BP binds R7–G
 
 
 
5 complexes
 
To determine whether R7BP binds R7 proteins, we performed
coimmunoprecipitation experiments using HEK293 cells that
coexpressed FLAG-tagged R7BP (FLAG-R7BP), MYC-
tagged G
 
 
 
5, and HA-tagged forms of RGS6, RGS7, RGS9-1,
RGS9-2, or RGS11. Immunoblotting of anti-FLAG immuno-
precipitates indicated that FLAG-R7BP bound G
 
 
 
5 and each
R7 family member (Fig. 3 A). Expression of R7BP moderately
increased the total levels of G
 
 
 
5 and R7 proteins, suggesting
that R7BP stabilizes G
 
 
 
5–R7 complexes. In the absence of an
R7 protein, G
 
 
 
5 did not associate with FLAG-R7BP (Fig. 3 B).
When G
 
 
 
5 was not coexpressed, an R7 family member
(RGS9-2) could bind FLAG-R7BP (Fig. 3 B), albeit less effi-
ciently. Therefore, R7BP binds the R7 subunit of the R7–G
 
 
 
5
complex; G
 
 
 
5 may promote this interaction by stabilizing or
changing the conformation of the R7 subunit. R7BP–R7 inter-
action was specific because tagged forms of two RGS proteins
of a different subfamily (RGS2 and RGS4 of the R4 family)
that do not bind G
 
 
 
5 were undetectable in FLAG-R7BP immu-
noprecipitates (Fig. 3 C).
 
R7BP recruits R7 RGS proteins to the 
plasma membrane
 
To determine whether R7BP associates with cell membranes
and recruits R7 family members, we performed confocal mi-
croscopy experiments with cells expressing R7BP tagged at its
NH
 
2
 
 terminus with GFP or FLAG. The results showed that
GFP- or FLAG-R7BP localized primarily to the plasma mem-
brane as well as the cytoplasm and nucleus (Fig. 4 A). Quanti-
fication of confocal images indicated that 
 
 
 
40% of GFP-R7BP
(SEM 15%; 
 
n
 
 
 
  
 
30 cells) was nuclear, whereas the remainder
localized to the plasma membrane or cytoplasm.
Results of similar experiments indicated that R7BP re-
cruits each R7 family member to the plasma membrane. We
expressed MYC-tagged G
 
 
 
5 to stabilize expression of HA-
tagged R7 subunits. In the absence of R7BP, R7 proteins failed
to associate detectably with the plasma membrane (Fig. 4 B)
Figure 2. R7BP mRNA is highly and broadly expressed in brain. (A)
Northern blot analysis of R7BP mRNA expression. A probe consisting of
the R7BP open reading frame was used to detect R7BP mRNA in a mouse
multiple tissue Northern blot. The same blot was stripped and probed for
 -actin mRNA. (B) In situ hybridization analysis of R7BP mRNA expression
in mouse brain. An antisense RNA probe for the R7BP open reading
frame was hybridized to coronal sections of mouse brain followed by
autoradiography. A labeled RNA sense probe was hybridized to half-
brain coronal sections as a specificity control. (C) In situ analysis performed
as in B, except that sagittal sections were analyzed. A representative medial
(left) and a lateral (right) section are shown. ctx, neocortex; cpu, caudate/
putamen (striatum); th, thalamus; hp, hippocampus; pf, piriform cortex;
ob, olfactory bulb; cbl, cerebellum.
Figure 3. R7BP interacts with R7 RGS proteins. (A) R7BP binds each of
the five R7 RGS proteins. HEK293 cells were transfected with plasmids
encoding an HA-tagged R7 RGS protein (RGS6, RGS7, RGS9-1, RGS9-2,
or RGS11) and MYC-tagged versions of G 5 with or without a FLAG-
tagged version of R7BP. FLAG antibody immunoprecipitates were assayed
for the presence of the RGS and G 5 proteins by blotting with the indi-
cated antibodies. Western blots of total cell lysates indicated the levels of
the expressed proteins. (B) R7BP forms a complex with R7–G 5 proteins.
HEK293 cells were transfected with different combinations of plasmids
expressing the indicated tagged forms of R7BP, RGS9-2, and G 5. FLAG-
R7BP was immunoprecipitated, and the precipitated material and total cell
lysates were analyzed as in A. (C) R7BP does not interact with R4 family
RGS proteins. Plasmids encoding a GFP-tagged form of RGS4 or a 3MYC-
tagged version of RGS2 were transfected into HEK293 cells along with
FLAG-R7BP. The presence of RGS2 or RGS4 in the FLAG-immunoprecipitate
and total lysate was assayed by Western blotting. 
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and were cytoplasmic (RGS6, 7, 9–1 and 11) or nuclear
(RGS9-2), which is in agreement with previous studies. In con-
trast, coexpression of GFP-R7BP resulted in efficient recruit-
ment of each HA-R7 protein to the plasma membrane coinci-
dent with the localization of GFP-R7BP (Fig. 4 B). This effect
was specific for the R7 family because FLAG-R7BP failed to
recruit GFP-RGS4 to the plasma membrane (Fig. 4 C). There-
fore, R7BP is a plasma membrane–anchoring protein specific
for the R7 family of RGS proteins.
 
Palmitoylation of R7BP
 
R7BP possesses a dicysteine motif near its COOH terminus
(CCLVSS-COOH) that is a potential lipid modification site
(Fig. 5 A). This sequence resembles the COOH terminus of
H-Ras (CCAAX-COOH), which is palmitoylated and prenylated
(for reviews see Zhang and Casey, 1996; Smotrys and Linder,
2004). However, the COOH-terminal region of R7BP contains
four rather than three amino acids after the last cysteine, which
should preclude prenylation by displacing this residue from the
prenyltransferase active site (Long et al., 2002).
We investigated the roles of COOH-terminal cysteine
residues in GFP-tagged R7BP by changing either or both to
serine. We then analyzed the localization of wild-type and mu-
tant proteins expressed in HEK293 cells or primary rat hippo-
campal neurons. Wild-type GFP-R7BP localized to the plasma
membrane and nuclei of HEK293 cells and punctate dendritic
structures and nuclei of hippocampal neurons (Fig. 5, B and C).
In contrast, the C253S single mutant or the C252S/C253S dou-
ble mutant form of GFP-R7BP did not concentrate on the
plasma membrane of HEK293 cells or dendritic foci in neurons
but instead was cytoplasmic and/or nuclear localized (Fig. 5, B
and C). The C252S mutant exhibited a localization phenotype
intermediate between the wild-type protein and other mutants
(Fig. 5 B). Quantification of confocal images indicated that
whereas 
 
 
 
40% of wild-type GFP-R7BP was nuclear in HEK293
cells (SEM 15%; 
 
n
 
 
 
  
 
30 cells), 
 
 
 
80% of the GFP-R7BP-
C252S/C353S double mutant was nuclear (SEM 8%; 
 
n
 
 
 
  
 
30
cells). Similar results were obtained using wild type and mutant
forms of FLAG-tagged R7BP (Fig. S1, available at http://
www.jcb.org/cgi/content/full/jcb.200502007/DC1), indicating
that nuclear accumulation was not due to the presence of the
GFP tag. Thus, the COOH-terminal cysteine residues pro-
foundly regulate the distribution of R7BP between the plasma
membrane, cytoplasm, and nucleus. The R7BP cysteine mu-
tants migrated identically with wild-type R7BP upon SDS-
PAGE (unpublished data), suggesting that R7BP is not subject
to proteolytic processing characteristic of many prenylated pro-
teins (Zhang and Casey, 1996).
To determine whether R7BP is palmitoylated, we analyzed
the localization of GFP-R7BP when cells were treated with
agents that block palmitoylation or prenylation. Doses of 2-bro-
mopalmitate (2Br-palmitate) that block the modification of
known palmitoylated proteins strikingly decreased plasma mem-
brane localization of GFP-R7BP and increased nuclear localiza-
tion of the protein (Fig. 5 D). Quantification of confocal images
indicated that 
 
 
 
35% of GFP-R7BP in vehicle-treated cells was
nuclear (SEM 8%; 
 
n
 
 
 
  
 
30 cells), whereas 
 
 
 
67% of the protein in
2Br-palmitate–treated cells was nuclear (SEM 11%; 
 
n
 
 
 
  
 
30). In
contrast, neither a selective farnesyltransferase inhibitor (FTI-
277) nor a geranylgeranyltransferase inhibitor (GTI-298) resulted
in loss of GFP-R7BP from the plasma membrane (Fig. 5 E).
However, these inhibitors did disrupt the localization of farnesy-
lated and geranylgeranylated proteins (GFP–H-Ras and -Rap1A,
respectively; Fig. 5 F; Fukasawa et al., 2004).
Second, we determined whether FLAG-R7BP expressed
in HEK293 cells could be labeled with [
 
3
 
H]palmitate. Fluorog-
raphy of anti-FLAG immunoprecipitates resolved by SDS-
Figure 4. R7BP specifically recruits R7 RGS proteins to the plasma mem-
brane. (A) R7BP is a plasma membrane protein. HEK293 cells expressing
GFP-R7BP or FLAG-R7BP were analyzed by laser scanning confocal mi-
croscopy. (B) R7BP recruits R7 family RGS proteins to the plasma mem-
brane. Cells expressing HA-tagged R7 RGS proteins (RGS6, RGS7, RGS9-1,
RGS9-2, or RGS11) and MYC-G 5 were assayed for localization of the
R7 family member by immunofluorescence confocal microscopy in the pres-
ence or absence of coexpressed GFP-R7BP. Anti-HA indicates the loca-
tion of the RGS protein, whereas GFP-fluorescence indicates the localiza-
tion of R7BP. Colocalization of R7BP and the RGS protein was determined
by merging the data from the two channels; colocalization is indicated by
yellow. (C) RGS4 is not recruited to the plasma membrane by R7BP.
RGS4-GFP was coexpressed with FLAG-R7BP and the localization of these
proteins was determined by confocal microscopy. 
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PAGE revealed that wild-type R7BP but not a control protein
(FLAG-ERK2) was labeled with [
 
3
 
H]palmitate (Fig. 6 A).
Palmitate labeling of R7BP was reduced when cells expressed
the C252S or the C253S single mutants (Fig. 6 A), suggesting
that both cysteines are palmitoylated. Labeling was undetect-
able when both cysteines were changed to serine (Fig. 6 A).
Palmitate labeling of wild-type R7BP was reversed upon treat-
ing gels with neutral hydroxylamine (Fig. 6 B). Reverse-phase
thin layer chromatography indicated that the labeled lipid re-
leased from R7BP comigrated with C16:0 palmitate (Fig. 6 C)
rather than a palmitate metabolite. Together these results indi-
cated that labeled palmitate was attached to R7BP via a base-
labile thioester linkage characteristic of palmitoylated proteins.
 
R7BP binds R7 proteins independently 
of its palmitoylation state
 
Because R7 family members in brain localize both to the plasma
membrane and nucleus, plasma membrane–nuclear shuttling of
R7–G
 
 
 
5 complexes may be controlled by the palmitoylation
state of R7BP. This hypothesis requires that R7 proteins bind
palmitoylated or unpalmitoylated R7BP. Accordingly, we com-
pared the ability of RGS7–G
 
 
 
5 and RGS9-2–G
 
 
 
5 complexes to
bind FLAG-tagged forms of wild-type or nonpalmitoylated
(C252S/C253S; “SS” mutant) R7BP in coimmunoprecipitation
experiments. The results indicated that RGS7–G
 
 
 
5 and RGS9-
2–G
 
 
 
5 complexes bind wild-type or nonpalmitoylated R7BP
(Fig. 7, A and B). Likewise, the nonpalmitoylated R7BP mutant
recruited RGS7 or RGS9-1 to the nucleus (Fig. 7 C; RGS9-2
was used rather than RGS9-1 because the latter molecule local-
izes to the nucleus without R7BP). These results suggested that
palmitoylation/depalmitoylation of R7BP provides a mecha-
nism that controls shuttling of R7–G
 
 
 
5 complexes between the
plasma membrane and nucleus.
To test this hypothesis, we determined whether or not de-
palmitoylation of wild-type R7BP by endogenous protein-
thioesterase activity results in shuttling of R7BP–RGS9-1–
Figure 5. R7BP localization is palmitoylation dependent. (A) Schematic
diagram of the R7BP COOH terminus. Cysteine residues that were mutated
are indicated with an asterisk. (B) The R7BP double-cysteine motif is necessary
for plasma membrane localization. Plasmids encoding GFP-tagged wild
type and mutant forms of R7BP were transfected into HEK293 cells and
localized by confocal microscopy. The following mutants were used:
C252S, C253S, and a C252S/C253S double mutant. (C) R7BP local-
ization in neurons. Neonatal rat hippocampal neurons were transfected
with wild type or the C252S/C253S mutant form of GFP-R7BP and ana-
lyzed by confocal microscopy. High magnification images of a cell trans-
fected with wild-type GFP-R7BP show localization in the cell soma and
dendrites. (D) A palmitoylation inhibitor (2Br-palmitate) disrupts R7BP
membrane localization. HEK293 cells expressing wild-type GFP-R7BP
were treated with the indicated dose of 2Br-palmitate for 16 h, followed
by fixation and analysis by confocal microscopy. (E) Prenylation inhibitors
do not block R7BP plasma membrane localization. HEK293 cells expressing
GFP-R7BP were treated 16 h with vehicle (DMSO), a farnesyltransferase
inhibitor (FTI-277; 30  M), or a geranylgeranyltransferase inhibitor
(GGTI-298; 20  M). Fixed cells were analyzed by confocal microscopy.
(F) FTI and GGTI controls. HEK293 cells expressing GFP-H-Ras (farnesylated
protein) or GFP-Rap1A (geranylgeranylated protein) were treated with
vehicle or the indicated compounds as in E. Cells were fixed and analyzed
by confocal microscopy.
Figure 6. R7BP is palmitoylated at its COOH-terminal cysteine residues.
(A) Palmitate labeling of R7BP. HEK293 cells expressing wild type or
mutant (C252S, C253S, or C252S/C253S) FLAG-tagged forms of R7BP
were metabolically labeled with [
3H]palmitic acid or [
35S]methionine as a
control. FLAG-R7BP proteins were immunoprecipitated and resolved by
SDS-PAGE. Radiolabeled R7BP was detected by fluorography ([
3H]palmi-
tate; 7-d exposure) or autoradiography ([
35S]methionine; 4-h exposure) of
dried gels (left). Expression and labeling controls for FLAG-R7BP and the
control protein FLAG-ERK2 are shown in the right panel (13-d expo-
sure for 
3H-labeled samples). (B) Palmitate is attached to R7BP by a thio-
ester linkage. HEK293 cells expressing FLAG-R7BP were labeled with
[
3H]palmitic acid or [
35S]methionine followed by immunoprecipitation
with FLAG-M2 agarose. Immunoprecipitates resolved on duplicate gels
were treated with 0.5 M Tris, pH 7.0, or 0.5 M hydroxylamine, pH 7.0,
and analyzed by fluorography (12-d exposure) and autoradiography
(16-h exposure). (C) R7BP is labeled with palmitate. HEK293 cells expressing
FLAG-R7BP or FLAG-ERK2 proteins were labeled with [
3H]palmitic acid,
immunoprecipitated, resolved by SDS-PAGE, and excised from the gel.
Fatty acids were released from samples by base treatment and analyzed
by fractionation on reverse-phase TLC plates relative to the indicated
standards (18-d exposure).JCB • VOLUME 169 • NUMBER 4 • 2005 628
G 5 complexes to the nucleus. We treated cells coexpressing
GFP-R7BP, HA-RGS9-1, and MYC-G 5 with cycloheximide
to block new protein synthesis. As R7BP was depalmitoylated,
it was trapped in the unmodified state by blocking repalmitoy-
lation with 2Br-palmitate. Confocal imaging at various times
after drug treatment was used to detect translocation of GFP-
R7BP and HA-RGS9-1 from the plasma membrane to the nu-
cleus (Fig. 7 D). Quantification of the images indicated that
immediately after drug treatment  90% of cells showed colo-
calization of GFP-R7BP and HA-RGS9-1 at the plasma mem-
brane. In striking contrast, within 6 h after drug treatment
 65% of cells exhibited colocalization of R7BP and RGS9-1
in the nucleus. The time course of R7BP translocation to the
nucleus was similar to the basal rate with which signaling pro-
teins are depalmitoylated in cells (for review see Smotrys and
Linder, 2004). Therefore, these results indicated that R7BP
palmitoylation/depalmitoylation regulates plasma membrane–
nuclear shuttling of R7BP–R7–G 5 complexes.
R7BP augments RGS7-mediated 
regulation of G protein–regulated inward 
rectifying potassium (GIRK) channel 
activity
To determine whether or not R7BP affects R7 protein function,
we performed experiments that used G protein–mediated acti-
vation of GIRK channels expressed in Xenopus laevis oocytes
as an assay (Doupnik et al., 2004). Because R7 proteins are
GAPs for Gi/o  subunits (Posner et al., 1999; Rose et al., 2000;
Hooks et al., 2003), we examined the effects of R7BP on GIRK
channels activated by m2 muscarinic acetylcholine (ACh)
receptors selectively coupled to Go  using pertussis toxin
(PTX)-insensitive Go A(C351A) (Zhang et al., 2002). As
shown in Fig. 8 A, in this system GFP-R7BP dramatically ac-
celerated the kinetics of ACh-activated GIRK currents; this
robust effect depended on coexpression with RGS7–G 5
complexes. Coexpression of RGS7–G 5 and GFP-R7BP ac-
celerated the kinetics of GIRK channel deactivation, activa-
tion, and acute desensitization, which are the hallmarks of
GIRK channel modulation by the GAP activity of RGS pro-
teins (Doupnik et al., 1997; Saitoh et al., 1997; Chuang et al.,
1998).
To quantify the effects of GFP-R7BP, we varied the ex-
pression levels of RGS7–G 5 by injecting increasing amounts
of cRNA. In the absence of GFP-R7BP, increasing the expres-
sion of RGS7–G 5 moderately accelerated the rate of GIRK
current deactivation (Fig. 8 B), as previously reported (Kovoor et
al., 2000). Further increases in RGS7–G 5 expression (or RGS7
alone) resulted in marked suppression of GIRK current ampli-
tude (unpublished data), as demonstrated previously (Zhang et
al., 2002). At the lowest level of RGS7–G 5 expression (0.1 ng
Figure 7. R7BP binds to R7 proteins independently of its
palmitoylation state. (A)  RGS7 binds wild type or the
C252S/C253S mutant form of R7BP. Wild-type or mutant
(SS) FLAG-R7BP was expressed in HEK293 cells with HA-
RGS7 and MYC-G 5. FLAG immunoprecipitates and total
lysates were resolved on SDS–polyacrylamide gels and blotted
for the expressed proteins. (B) RGS9-2 binds wild type or the
C252S/C253S mutant form of R7BP. Methods were identical
to A except that HA-tagged RGS9-2 was expressed. (C) Un-
palmitoylated R7BP recruits R7 proteins to the nucleus. Exper-
iments were performed identically to those shown in Fig. 4 B
except that the C252S/C253S double mutant form of R7BP
was used. (D) Depalmitoylation of R7BP results in translocation
of RGS9-1 to the nucleus. HEK293 cells were transfected
with plasmids expressing wild-type GFP-R7BP, HA-RGS9-1,
and MYC-G 5. Cells were treated at t   0 with cycloheximide
(30  g/ml) and 2Br-palmitate (10  M) to block, respectively,
new protein synthesis and repalmitoylation of R7BP that had
been depalmitoylated by endogenous thioesterase activity.
Confocal microscopy was used to analyze cells fixed at the
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each cRNA/oocyte), GFP-R7BP (5 ng cRNA/oocyte) had an in-
significant effect on GIRK current deactivation rate (Fig. 8 B).
However, at moderate (1 ng each cRNA/oocyte) or higher (5 ng
each cRNA/oocyte) RGS7–G 5 expression, GFP-R7BP signifi-
cantly increased the rates of agonist-independent GIRK deacti-
vation (Fig. 8 B) and agonist-dependent activation (Fig. 8 C)
four- to fivefold. Coexpression of GFP-R7BP and RGS7–G 5 at
these levels did not significantly change the ACh dose–response
relation (Fig. 8 D). Together, these functional effects are consis-
tent with previous studies implicating the existence of GPCR-
GIRK channel signaling complexes that include RGS proteins
(Sadja et al., 2003; Benians et al., 2005). Therefore, our findings
indicate R7BP strikingly facilitates the formation of GIRK chan-
nel signaling complexes containing R7 RGS proteins.
Finally, to determine whether or not palmitoylation of
R7BP affects its ability to augment RGS7–G 5 activity, we
examined the effects of palmitoylation-deficient GFP-R7BP
(C252S/C253S; “SS” mutant). By varying RGS7–G 5 expres-
sion level, we found that GFP-R7BP-SS had an insignificant
effect on GIRK channel deactivation rates at low level of RGS7–
G 5 (1 ng cRNA/oocyte) and diminished effect relative to wild-
type GFP-R7BP at higher level of RGS7–G 5 expression (5 ng
cRNA/oocyte; Fig. 8 B). The effects of R7BP palmitoylation on
GIRK channel activation kinetics were examined at a fixed
RGS7–G 5 expression level (1 ng each cRNA/oocyte) by vary-
ing the ACh dose (Fig. 8 C). These results indicated that non-
palmitoylated GFP-R7BP-SS exhibited significantly reduced
activity relative to wild-type GFP-R7BP. The palmitoylation-
independent effects of mutant R7BP may occur by stabilizing
RGS7–G 5 complexes and/or augmenting the GAP activity of
RGS7–G 5 complexes, similar to what has been shown with
R9AP and RGS9-1 (Lishko et al., 2002; Hu et al., 2003). Never-
theless, because wild-type R7BP exhibited significantly greater
activity relative to nonpalmitoylated R7BP, we conclude that
palmitoylation of R7BP is required for efficient targeting of
R7BP–RGS7–G 5 complexes to the plasma membrane, thereby
facilitating modulation of receptor-coupled GIRK channels.
Discussion
We identify R7BP as a novel palmitoylated protein that regu-
lates plasma membrane–nuclear shuttling of any member of the
RGS7 (R7) family of G protein regulators bound to G 5. We
suggest that R7BP is the principal plasma membrane–anchor-
ing protein for R7–G 5 complexes in the nervous system be-
cause: (a) R7BP, G 5, and R7 proteins are expressed highly
only in the nervous system (Gold et al., 1997; Zhang et al.,
2000; Larminie et al., 2004), in contrast to the R7 anchor
R9AP, which is expressed highly only in retina (Hu and
Wensel, 2002); (b) R7BP and R9AP are the only closely re-
lated members of this protein family of membrane anchors; and
(c) the spatial expression of R7BP, G 5, and the R7 family in
brain are highly coincident (results presented herein; Gold et
al., 1997; Zhang et al., 2000).
In parallel with our studies, Martemyanov et al. (2005)
recently identified R7BP as a protein that copurifies nearly stoi-
chiometrically with RGS9-2–G 5 complexes isolated from
brain extracts. They showed that recombinant R7BP interacts
in vitro with each R7 isoform, that endogenously expressed
R7BP and each R7 isoform can be coprecipitated from brain
membrane extracts, and that R7BP protein is expressed highly
in various brain regions and in retina but not in several other
tissues. These findings complement our results showing that
R7BP is as a palmitoylation-regulated plasma membrane–
nuclear shuttling protein that augments R7 protein function by
targeting them to the plasma membrane. Thus, there is strong
evidence that R7BP is the primary membrane anchoring pro-
tein for R7 family members in the nervous system.
Why do vertebrate genomes encode two distinct mem-
brane-anchoring proteins for the R7 family: R9AP in retinal
photoreceptor cells and R7BP throughout the nervous system?
The nonoverlapping expression patterns and different mem-
brane association mechanisms of R7BP and R9AP indicate that
these proteins have distinct physiologic and mechanistic func-
tions. R9AP may function constitutively as a membrane-anchor-
ing protein because it possesses a transmembrane domain.
R9AP also may possesses unique structural or sequence motifs
that target R9AP–RGS9-1–G 5L complexes to outer segments
of photoreceptor cells, analogous to the outer segment-targeting
domain at the COOH terminus of rhodopsin (Tam et al., 2000).
Figure 8. R7BP augments RGS7–G 5–modulated GIRK currents activated
by Go -coupled m2 muscarinic receptors expressed in X. laevis oocytes
by a mechanism facilitated by its palmitoylation sites. (A) Superimposed
GIRK currents evoked by a range of ACh concentrations (25-s application)
from individual oocytes under three different expression conditions. Left
traces, control conditions (no R7BP expression); center traces, GFP-R7BP
expression (5 ng cRNA/oocyte); right trace, palmitoylation-deficient GFP-
R7BP-C252S/C253S mutant expression (GFP-R7BP-SS, 5 ng cRNA/oocyte).
All oocytes were injected with cRNAs for RGS7 and G 5 (1 ng each/
oocyte), and equivalent amounts of Kir3.1, Kir3.2a, muscarinic m2 receptor,
Go A (C351G), and pertussis toxin (PTX-S1; see Materials and methods
for details). Bars indicate 1  A and 10 s. (B) R7BP accelerates GIRK
current deactivation kinetics by a mechanism dependent on RGS7–G 5
concentration and R7BP palmitoylation sites (C252 and C253). Derived
time constants for GIRK deactivation after application of 10  M ACh at
three levels of RGS7–G 5 expression, with coexpression of either GFP-
R7BP (5 ng cRNA/oocyte) or GFP-R7BP-SS (5 ng cRNA/oocyte). (C) R7BP
accelerates GIRK current activation kinetics. Activation time constants
derived from the time course for GIRK current activation with different ACh
concentrations. (D) R7BP does not significantly affect the ACh dose–response
relation for steady-state GIRK current activation or the maximal GIRK
current amplitude. Error bars show SEM.JCB • VOLUME 169 • NUMBER 4 • 2005 630
R7BP, in contrast, apparently functions as a regulated
plasma membrane–nuclear shuttling protein (Fig. 9). R7BP is
palmitoylated, a reversible lipid modification that profoundly
affects the localization and function of R7BP–R7–G 5 com-
plexes. Palmitoylation may target R7BP–R7–G 5 complexes
to lipid rafts or other specialized domains of the plasma mem-
brane, similar to other palmitoylated proteins (El-Husseini and
Bredt, 2002). Indeed, in hippocampal neurons GFP-R7BP con-
centrates in dendritic foci, as do the neuronal palmitoylated
proteins PSD-95 and GAP-43 (El-Husseini and Bredt, 2002).
More strikingly, palmitoylation regulates shuttling of R7BP–
R7–G 5 complexes between the plasma membrane and nucleus.
Accordingly, we hypothesize that reversible palmitoylation of
R7BP provides a novel plasticity or “tuning” mechanism that
modulates GPCR signaling. Depalmitoylation of R7BP and
consequent delocalization of R7BP–R7–G 5 complexes
from the plasma membrane may sensitize signaling mediated
by Gi/o-coupled GPCRs. Palmitoylation of R7BP could have
the opposite effect by attenuating or desensitizing signaling via
Gi/o-coupled receptors or it could enable R7–G 5 complexes
transduce signals to plasma membrane effectors.
If R7BP depalmitoylation occurs after GPCR activation,
R7BP–R7–G 5 complexes would be targeted to the nucleus.
Because the R7 protein RGS6 can regulate gene expression
(Liu and Fisher, 2004), signal-triggered depalmitoylation of
R7BP could provide a novel mechanism for transmitting
GPCR signals directly from the plasma membrane to the nu-
cleus. Conversely, signal-regulated palmitoylation of R7BP
could recruit quiescent nuclear R7–G 5 complexes to the
plasma membrane to regulate GPCR signaling. These hypothe-
ses are supported by evidence indicating that endogenously ex-
pressed R7 proteins and G 5 in neurons localize to membranes
and nuclei (Zhang and Simonds, 2000; Bouhamdan et al.,
2004; Krumins et al., 2004) and that GPCR activation can reg-
ulate the palmitoylation status of signaling proteins (for review
see Smotrys and Linder, 2004).
Palmitoylation-regulated translocation of R7BP–R7–G 5
complexes to and from the plasma membrane would have pro-
found consequences for GPCR-mediated regulation of ion
channels and neuronal excitability. The concentration-depen-
dent kinetic effects of RGS7 toward m2 receptor/Go –coupled
GIRK channel activity and the augmented effects caused
by R7BP coexpression indicate that palmitoylation-regulated
R7BP–R7–G 5 translocation controls both the amplitude and
kinetics of ion channels regulated by Gi/o-coupled receptors,
especially GIRK channels and voltage-gated calcium channels
(Wickman and Clapham, 1995). Palmitoylated R7BP also may
promote GPCR-selective ion channel regulation by targeting
specific GPCR–R7–ion channel complexes to lipid rafts where
Go, selected GPCRs, and ion channels colocalize (Cabrera-
Vera et al., 2004).
R7BP may prove to be crucial for several functions of the
central and peripheral nervous systems. This hypothesis is
based on evidence indicating that the R7 substrate Go  is re-
quired in the central nervous system for regulation of motor
control, motor behavior, and pain sensation (Jiang et al., 1998),
and in retinal “ON” bipolar cells for light response (Dhingra et
al., 2002). It also is suggested by evidence indicating that
RGS9 is required to regulate antinociception via  -opioid re-
ceptors and locomotor activity via D2 dopamine receptors
(Rahman et al., 2003; Zachariou et al., 2003).
In conclusion, many neuronal signaling proteins includ-
ing  -adrenergic receptors, G protein   subunits, R7BP, sev-
eral RGS isoforms, PSD-95, nonreceptor tyrosine kinases, and
H-ras are palmitoylated (for reviews see El-Husseini and Bredt,
2002; Smotrys and Linder, 2004). The diversity of palmitoy-
lated proteins and the large family enzymes that palmitoylate
them (Fukata et al., 2004) raise intriguing questions about how
palmitoylation occurs in a specific and regulated manner to
modulate nervous and sensory system function. Further analy-
sis of R7BP palmitoylation may reveal novel mechanistic prin-
ciples applicable to a variety of neuronal signaling proteins.
Materials and methods
Reagents and antibodies
For Western blots, anti-FLAG-M2 HRP conjugate (Sigma-Aldrich) was used
at a dilution of 1:5,000, anti-MYC 9E10 HRP conjugate (Roche) at
1:1,000, anti-HA 12CA5 HRP conjugate (Roche) at 1:2,000, and HRP-
conjugated goat anti–mouse secondary antibodies (Pierce Chemical Co.)
at 1:10,000. For immunofluorescence, the anti-HA-11 antibody (BAbco)
was used at a dilution of 1:500, anti-FLAG M2 (Sigma-Aldrich) at 1:1,000,
and goat anti–mouse Alexa 568 secondary (Molecular Probes) at 1:100.
2Br-palmitate was obtained from Sigma-Aldrich. Hydroxylamine and so-
dium salicylate were purchased from Fisher Scientific. FTI-277 and GGTI-
298 were obtained from Calbiochem. Unless noted otherwise, all chemi-
cals were obtained from Sigma-Aldrich.
Cell culture and transfection
HEK293 cells (American Type Culture Collection) were maintained and
transfected in DME/F12 with 10% FBS (Atlanta Biologicals) plus penicil-
lin/streptomycin. Cells were grown at 37 C and 5% CO2. Transfection of
Figure 9. Regulation of the RGS7 family and G 5 by R7BP palmitoylation.
R7BP, G 5, and an R7 family member form a trimolecular complex. R7BP
is palmitoylated and recruits R7BP–R7–G 5 complexes to the plasma
membrane where they regulate GPCR signal transduction. Upon depalmi-
toylation of R7BP, either unregulated or signal-induced R7BP–R7–G 5
complexes release from the plasma membrane and translocate to the
nucleus where they potentially regulate gene expression or other processes.
Unpalmitoylated R7BP–R7–G 5 complexes may shuttle between the nucleus
and cytoplasm, allowing them to become palmitoylated and targeted to
the plasma membrane. RGS7 can be palmitoylated (Rose et al., 2000;
Takida et al., 2005), which may influence trafficking and function of
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HEK293 cells was performed using Effectene (QIAGEN) according to the
manufacturer’s instructions. Neonatal rat hippocampal neurons were iso-
lated and cultured on glass coverslips coated with laminin and poly-D,L-orni-
thine as described previously (Wilding and Huettner, 2001). Neurons
were transfected with R7BP plasmids via calcium phosphate precipitation.
R7BP cloning
RNA was prepared from adult male mouse brain using TRIZOL (Invitrogen)
according to the manufacturer’s instructions. 1  g of total RNA was used
in a reverse transcriptase reaction using oligo-dT primers and Superscript
II (Invitrogen) according to manufacturer’s instructions. cDNA from reverse
transcriptase reactions was used as template for PCR to amplify the coding
region of R7BP using the following primers that included engineered
BamHI and EcoRI sites: 5 -gtggatccgtatgcatgagttctg-3 ; 5 -aagaattcagcat-
agaaaacatgg-3 . A 904-bp PCR product was generated, which subse-
quently was cloned into the BamHI–EcoRI sites of pcDNA3.1. The entire
insert was sequenced and found to be identical to a consensus cDNA se-
quence for R7BP that was generated by assembling all sequence informa-
tion from publicly available cDNA and EST databases. Database searches
identified putative R7BP homologues in the following species: human
(XP_376386), orangutan (CAH92694), chimpanzee (XP_518191),
mouse (BAC32849), rat (XP_215473), African clawed frog
(AAH73094), spotted green pufferfish (CAF93443), pig (CO949728),
chicken (BI390910), dog (CO656749), zebra finch (CK317390), ze-
brafish (CK363290), Salmo salar (CB513384), Oncorhynchus mykiss
(CA386277).
Plasmids
R7BP was fused to the COOH terminus of GFP by cloning a BamHI–EcoRI
fragment containing R7BP into the BglII–EcoRI sites of pEGFP-C1 (CLON-
TECH Laboratories, Inc.). 3FLAG-R7BP was constructed by cloning a Hind-
III–EcoRI fragment containing the R7BP coding region into p3FLAG-
CMV10 (Sigma-Aldrich). pBlueScript-R7BP was constructed by cloning a
BamHI–EcoRI fragment containing the R7BP coding region into pBlue-
Script II SK( ). Plasmids expressing HA-tagged versions of RGS6, RGS7,
RGS9-1, RGS9-2, and RGS11 along with a FLAG-tagged version of G 5
were gifts of T.K. Harden (University of North Carolina, Chapel Hill, NC).
A MYC-tagged version of G 5 was constructed by amplifying the G 5
coding region (flanked with BamHI and XhoI sites) from FLAG-G 5. This
PCR product was digested and cloned into the BamHI–XhoI sites of pCMV-
Tag 3A (Stratagene) to create a MYC-tagged fusion protein. RGS4-GFP
was generated by cloning a fragment containing the complete RGS4-GFP
fusion from pVT-RGS4-GFP (Srinivasa et al., 1998) into pCR3 for expres-
sion in mammalian cells. GFP-tagged versions of Rap1A and H-Ras were
gifts of M. Phillips (New York University School of Medicine, New York,
NY). A FLAG-tagged ERK2 plasmid was a gift of M. Weber (University of
Virginia Health Sciences Center, Charlottesville, VA). R7BP point mutants
were generated using Quickchange (Stratagene) according to the manu-
facturer’s instructions. All constructs and point mutants were verified by
DNA sequencing.
Cell lysis, immunoblotting, and immunoprecipitation
Cells were washed once with ice cold PBS and lysed in lysis buffer (MCLB:
50 mM Tris, pH 8.0, 5 mM EDTA, 0.5% NP-40, 100 mM NaCl, 1 mM so-
dium orthovanadate, and 1 mM PMSF) supplemented with protease inhibi-
tor tablets (Roche). Cells were incubated at 4 C for 5 min with MCLB fol-
lowed by further lysis by end-over-end rotation at 4 C for 15 min. Cell
debris and unbroken cells were pelleted by centrifugation (15,000 g) for 10
min at 4 C. Supernatant fractions were used directly for Western blot analy-
sis or for immunoprecipitation. For Western blots, 50–100  g of total pro-
tein was electrophoresed through 10% SDS–polyacrylamide gels followed
by transfer to PVDF (Millipore) membranes. Membranes were blocked for
1 h in 5% milk/TBST followed by overnight incubation with primary anti-
bodies. HRP-conjugated primary antibodies were removed, membranes
were washed with TBST, and signal was detected with ECL reagent (Amer-
sham Biosciences). For some Westerns, primary antibody was washed and
membranes were incubated with HRP-conjugated secondary antibodies for
1 h followed by processing. For immunoprecipitation, cleared cell lysates
were incubated with 50  l of FLAG M2-agarose affinity gel (Sigma-Aldrich)
for 90 min followed by 3  5-min washes in MCLB. Immunoprecipitates
were denatured with 1  SDS-sample buffer for 5 min at 100 C.
Northern blotting
The BamHI–EcoRI fragment encoding R7BP in pcDNA3.1 was used as a
template for random priming reactions (RediPrime II labeling system; Am-
ersham Biosciences) to generate a radiolabeled probe with Redivue stabi-
lized  -[
32P]dCTP (Amersham Biosciences). This probe and one for  -actin
were used to detect their cognate mRNAs in a mouse multiple tissue North-
ern blot containing poly(A) RNA (BD Biosciences) according to the manu-
facturer’s instructions.
In situ hybridization
Antisense and sense R7BP cRNA probes labeled with  -[
33P]UTP were
generated by run-off transcription using T7 RNA polymerase. C57/B6
adult male mice were transcardially perfused with 20 ml D-PBS (DEPC
treated) followed by fixation with 4% PFA in D-PBS (DEPC treated). Brains
were removed and immersion fixed for an additional 24 h at 4 C in 4%
PFA in D-PBS, and transferred to 10% sucrose in DEPC D-PBS for 36 h.
Brains were frozen in OCT in a dry ice-ethanol bath and cut into 20- m
sections (coronal or sagittal). Sections were fixed at RT under vacuum, fol-
lowed by in situ analysis as described previously (Muglia et al., 1999),
with the following modifications. Slides were digested with 0.001% pro-
teinase K, rinsed in 0.1 M TEA, and followed by blocking in 0.25% acetic
anhydride. Slides were washed in 2  SSC followed by dehydration in a
graded ethanol series (50%, 75%, 95%, 100%). Slides were dried under
vacuum followed by hybridization at 58 C for 20 h in a humidified cham-
ber. Slides were washed with 4  SSC, RNase-treated, rinsed, and de-
salted in a graded SSC series (2 , 1 , 0.5 ), and then dehydrated in a
graded ethanol series. Slides were dried under a vacuum and exposed to
film for 20–40 h.
Confocal immunofluorescence microscopy
Cells were grown and transfected on glass coverslips before preparation
for microscopy as follows. Cells were washed with PBS, fixed for 10 min
in fixative (3% PFA and 2% sucrose in PBS, pH 7.0) at 37 C, washed in
PBS, and, if immunofluorescence was performed, permeabilized in ice-
cold buffer (20 mM Hepes, pH 7.4, 0.5% Triton X-100, 50 mM NaCl, 3
mM MgCl2, and 300 mM sucrose). Cells were washed with PBS, blocked
with 0.1% BSA (in PBS) for 10 min at 4 C, and washed again with PBS.
Cells were incubated with primary antibodies (diluted in 5% goat serum/
TBST) for 20 min at 37 C in a humidified chamber followed by 10 consec-
utive washes in TBST. Secondary antibodies (diluted in 5% goat serum/
TBST) were incubated with cells for 15 min at RT followed by 10 washes
in TBST. Cells were mounted on slides for confocal microscopy. Confocal
microscopy was performed with a laser scanning confocal microscope
(model LSM-510; Carl Zeiss MicroImaging, Inc.). GFP-R7BP localization in
medial confocal sections of z-axis stacks was quantified by using Adobe
Photoshop to determine integrated pixel intensities in the nucleus versus
the entire cell and expressing the data as a nuclear/total cell ratio.
Metabolic labeling
HEK293 cells were grown and transfected in 6-well plates for labeling ex-
periments. For [
35S]methionine labeling, cells were starved 60 min of me-
thionine (methionine-free DME/F12 with sodium pyruvate and penicillin/
streptomycin) followed by labeling for 90 min in labeling media (starva-
tion media plus 10% dialyzed FBS and [
35S]methionine [Amersham Bio-
sciences] at 100  Ci per well). After labeling, cells were lysed and pro-
cessed for immunoprecipitation. After SDS-PAGE, gels were dried and
exposed to film at  70 C. For [
3H]palmitate labeling, cells were washed
with media (DME/F12 with sodium pyruvate, nonessential amino acids,
and penicillin/streptomycin) and incubated with labeling media for 90
min (media plus 10% dialyzed FBS and [
3H]palmitic acid [PerkinElmer] at
1 mCi per well). Cell lysis, immunoprecipitation, and SDS-PAGE were
performed as described for [
35S]methionine labeling. Gels containing
[
3H]palmitate were treated with fluor solution (1 M sodium salicylate in
15% methanol) for 30 min before drying and fluorography at  70 C.
For hydroxylamine treatment, gels containing either [
35S]methionine- or
[
3H]palmitate-labeled R7BP were treated overnight with 0.5 M NH2OH,
pH 7.0, or 0.5 M Tris, pH 7.0, in 50% 2-propanol. Gels were washed
several times over 2 d with 50% 2-propanol before fluorography.
Lipid analysis
Cells transfected with either FLAG-R7BP or FLAG-ERK2 were labeled with
[
3H]palmitic acid. Cells were lysed, immunoprecipitated with anti-FLAG
antibodies, and resolved on SDS-polyacrylamide gels. FLAG-tagged pro-
teins were excised from the gel and subjected to treatment with NaOH, as
described previously (Linder et al., 1995). Lipids were extracted from
base hydrolysates with chloroform/methanol (1:2), dissolved in chloro-
form, spotted on reverse-phase TLC plates (Whatman) along with 
3H-
labeled C14:0, C16:0, and C18:0 standards. Plates were developed in
acetonitrile/acetic acid (9:1), dried, sprayed with EN
3HANCE (Perkin-
Elmer), and exposed to film at  70 C.JCB • VOLUME 169 • NUMBER 4 • 2005 632
Electrophysiology
All procedures for the use and handling of X. laevis (Xenopus One) were
approved by the University of South Florida Institutional Animal Care and
Use Committee in accordance with National Institutes of Health guide-
lines. Oocytes were enzymatically isolated from ovarian tissue as de-
scribed previously (Zhang et al., 2002). Stage V–VI oocytes were selected
and maintained in oocyte culture medium (OCM) at 19 C in 35-mm
dishes on an orbital shaker. OCM was changed one to two times daily
and was composed of 82.5 mM NaCl, 2.5 mM KCl, 1.0 mM CaCl2, 1.0
mM MgCl2, 1.0 mM NaHPO4, 2.5 mM Na-pyruvate, and 5.0 mM Hepes,
pH 7.5, containing 2% heat-inactivated horse serum.
The effects of R7BP on GIRK channels activated by G o-coupled
muscarinic m2 receptors were examined with and without RGS7 coex-
pression in experimental groups of oocytes injected with different mixtures
of cRNAs synthesized in vitro from linearized cDNA vectors (mMessage
mMachine; Ambion). Stock cRNAs for each cDNA were dissolved in
DEPC-treated water and concentrations quantified by spectrophotometric
absorbance at 260 nm. Absorbance profiles from 220 to 320 nm were
performed to assess the quality of the stock cRNAs. Mixtures of different
cRNAs were prepared in DEPC-treated H2O so that amounts of each
cRNA injected per oocyte reflected that from a 50-nl injection of the cRNA
mixture using a positive-displacement nanoliter injector (Nanoliter2000;
World Precision Instruments). All experimental groups were injected with
cRNAs for rat Kir3.1 (0.5 ng/oocyte), mouse Kir3.2a (0.5 ng/oocyte),
human m2 muscarinic receptor (0.5 ng/oocyte), PTX-insensitive mouse
G oA(C352G) mutant subunit (5 ng cRNA/oocyte), and PTX-S1 cRNA (1
ng/oocyte) to inactivate endogenous G i/o subunits (Zhang et al., 2002).
Agonist-activated GIRK currents (IK,ACh) and receptor-independent
basal GIRK channel activity (IK,basal) were measured for each of the various
experimental groups by two-electrode voltage clamp recording (Gene-
Clamp 500; Axon Instruments, Inc.). Electrodes were constructed from
borosilicate glass capillary tubes (1.5-mm outside diameter, 0.86-mm in-
side diameter; GC150F-10; Warner Instruments) using a programmable
microelectrode puller (P-97; Sutter Instrument Co.). The electrodes had tip
resistances of 0.8–1.0 M  after filling with 3 M KCl. Membrane currents
from voltage clamped oocytes were digitized (Digidata 1200 acquisition
system; Axon Instruments, Inc.) and stored on a PC computer running
pCLAMP 8.0 software (Axon Instruments, Inc.).
Oocytes were initially superfused with a minimal salt solution com-
posed of 98 mM NaCl, 1 mM MgCl2, and 5 mM Hepes, pH 7.5
(NaOH). After electrode impalement and clamping the membrane poten-
tial to  80 mV, the solution was changed to a high K
  solution composed
of 20 mM KCl, 78 mM NaCl, 1 mM MgCl2, and 5 mM Hepes, pH 7.5
(NaOH). High K
  induced an inward current (IK,basal) that is comprised pri-
marily of receptor-independent GIRK channel activity (Dascal et al.,
1993). Rapid application and washout of a range of ACh concentrations
(Sigma-Aldrich) was performed with a computer controlled superfusion
system (SF-77B; Warner Instruments; Doupnik et al., 2004). Voltage
ramps from  80 to  20 mV and 1 s in duration were evoked before and
during agonist application to monitor inward rectification of the ACh-
evoked current. All recordings were performed at RT (21–23 C). GIRK
current deactivation kinetics were analyzed using pCLAMP software to de-
rive deactivation time constants ( deact) associated with agonist washout.
Statistical comparisons between the various experimental groups were
performed by one-way ANOVA where P   0.05 was considered signifi-
cant. Experiments were each replicated in oocytes from two separate
batches (dissections) of oocytes.
Online supplemental material
Fig. S1 shows localization of FLAG-tagged wild type and palmitoylation
site mutant (C252S/C253S) R7BP expressed in HEK293 cells. Online
supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.20502007/DC1.
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